Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, R. Gervais et al. · The Lancet Oncology · 2012
Cited by 5,483 works. doi:10.1016/s1470-2045(11)70393-x
Authors
- Rafael Rosell
- Enric Carcereny
- R. Gervais
- Alain Vergnenégre
- Bartomeu Massutí
- Enriqueta Felip
- Ramón Palmero
- Ramón García-Gómez
- Cinta Pallarés
- José Miguel Sánchez
- Rut Porta
- Manuel Cobo
- Pilar Garrido
- Flavia Longo
- Teresa Morán
- Amelia Insa
- Filippo de Marinis
- R. Corre
- Isabel Bover
- Alfonso Illiano
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer